阿糖胞苷药物不良反应监测  

ARA-C Adverse Drug Reaction Monitoring

作　　者：杨毓章[1] 韩艳秋[2] 肖跃平[2] 邰秀珍[2] 爱民[1] 焦效兰[1] 

机构地区：[1]内蒙古医学院药理教研室,010059 [2]内蒙古医学院第一附属医院,010050

出　　处：《药物流行病学杂志》1996年第4期204-206,共3页Chinese Journal of Pharmacoepidemiology

基　　金：国家自然科学基金资助

摘　　要：为了研究阿糖胞苷(ARA-C)药物不良反应(ADRs)的规律性及其影响因素,对41例使用ARA-C治疗的内科血液病房住院患者(其中白血病患者38例)进行ADRs系统集中监测.41例中出现ARA-C的ADRs者32例,199例次(平均每例6.2±5.5例次).消化系ADRs发生率最高(30/41,73.2%),例次最多(154例次).ADRs表现中恶心呕吐最多(87例次),以下依次为,食欲不振,继发感染发热,腹泻腹痛及血常规异常等.ARA-C联合用药组(DA,HA,PA,OA,PMA)的ADRs程度较单用ARA-C组为重(P<0.05).In order to investigate the ARA-C Adverse Drug Reaction (ADRs), 41 patients who had received ARA-C in the Department of Hematology (38 of them were patients with leukemia) were studied for ADRs. 32 of 41 cases developed ARA-C(199 case-times, with a mean of 6.2±5.5 case-times). The ADRs in digestive system had the highest rate (30/41, 73.2% and 154 case-times). The nausea and vomiting were two most frequently seen adverse effects, followed by anorexia, secondary infection, fever, diarrhea, abdominal pain and abnormal blood picture as revealed by routine blood examination. The adverse effects with combination use (DA, HA, PA, OA and PMA) were more severe than single use.

关 键 词：阿糖胞苷 白血病 药物副作用 

分 类 号：R733.7[医药卫生—肿瘤]